We provide you with 20 years of free, institutional-grade data for GENE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GENE. Explore the full financial landscape of GENE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Genetic Technologies Limited(NASDAQ:GENE) 
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary ...
The information provided in this report about GENE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.